ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Sep 15, 2020||ENDRA Life Sciences to Attend Lake Street's Fourth Annual Best Ideas Growth (BIG4) Conference September 17, 2020|
|Sep 14, 2020||ENDRA Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020|
|Sep 02, 2020||ENDRA Life Sciences to Present at the LD Micro 500 Virtual Conference|
|Aug 27, 2020||ENDRA Life Sciences to showcase TAEUS(R) Technology at EASL International Liver Congress 2020|
|Aug 24, 2020||ENDRA Life Sciences to Receive $5 Million From Early Warrant Exercises|
|Day Range||0.7489 - 0.7900|
|52 Week Range||0.5990 - 2.2500|
|Bid/Ask||0.7510 / 0.7800|
|Bid/Ask Size||400 X 500|
|Market Cap||16.06 million|
|Shares Outstanding||20.96 million|
|Dividend/Yield||0.0000 / 0.0000%|
|P/E Ratio (TTM)||N/A|